This Small Cap Is Poised To Tap Multi-Billion Dollar Migraine Treatment Market
- IntelGenx co-developed VersaFilm, which provides new way for migraine sufferers to treat and ward off headaches.
- VersaFilm allows IntelGenx to tap a market $70 billion drug delivery market.
- Challenges include receiving FDA approval after prior failed attempts.
- As a long-term play, IntelGenx is worth considering.